Chinese Biotechs Partner Up 18.2-Targeting ADCs Amid Intense Domestic Competition

 
• By Dexter Jie Yan
More and more Chinese Biotechs are teaming up with larger-scale domestic pharma companies for wider market access.
Three deals for Claudin 18.2-targeting ADCs between China/US firms since May • Source: Alamy

More from China

More from Focus On Asia